- Home
- QIPT vs ONCY Comparison
QIPT vs ONCY Comparison
Compare QIPT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- ONCY
- Stock Information
- Founded
- QIPT 1993
- ONCY 1998
- Country
- QIPT United States
- ONCY Canada
- Employees
- QIPT N/A
- ONCY N/A
- Industry
- QIPT
- ONCY Pharmaceuticals and Biotechnology
- Sector
- QIPT
- ONCY Health Care
- Exchange
- QIPT Nasdaq
- ONCY Nasdaq
- Market Cap
- QIPT 92.2M
- ONCY 89.7M
- IPO Year
- QIPT N/A
- ONCY 1999
- Fundamental
- Price
- QIPT $2.14
- ONCY $1.09
- Analyst Decision
- QIPT Buy
- ONCY Strong Buy
- Analyst Count
- QIPT 2
- ONCY 4
- Target Price
- QIPT $2.85
- ONCY $4.33
- AVG Volume (30 Days)
- QIPT 285.8K
- ONCY 1.5M
- Earning Date
- QIPT 08-13-2025
- ONCY 08-08-2025
- Dividend Yield
- QIPT N/A
- ONCY N/A
- EPS Growth
- QIPT N/A
- ONCY N/A
- EPS
- QIPT N/A
- ONCY N/A
- Revenue
- QIPT $240,848,000.00
- ONCY N/A
- Revenue This Year
- QIPT $3.35
- ONCY N/A
- Revenue Next Year
- QIPT $5.39
- ONCY N/A
- P/E Ratio
- QIPT N/A
- ONCY N/A
- Revenue Growth
- QIPT N/A
- ONCY N/A
- 52 Week Low
- QIPT $1.35
- ONCY $0.33
- 52 Week High
- QIPT $4.07
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- QIPT 57.85
- ONCY 55.31
- Support Level
- QIPT $2.08
- ONCY $1.00
- Resistance Level
- QIPT $2.27
- ONCY $1.35
- Average True Range (ATR)
- QIPT 0.10
- ONCY 0.11
- MACD
- QIPT 0.03
- ONCY -0.03
- Stochastic Oscillator
- QIPT 72.63
- ONCY 25.71
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.